MA-BATTERY-VENTURES
15.4.2021 06:03:14 CEST | Business Wire | Press release
Battery Ventures, a global, technology-focused investment firm, has reached an agreement to acquire imc Test & Measurement (“imc”), a global provider of productive test and measurement hardware and software solutions. Joining Battery’s group of companies in the test and measurement market, imc will operate alongside U.S.-based Audio Precision and Denmark-based GRAS Sound & Vibration, which were acquired by Battery in 2018 and 2020, respectively. Terms of the transaction were not disclosed.
Founded in 1988, imc is a well-known provider of state-of-the-art data acquisition systems and software. The company serves customers in markets such as automotive, energy, rail and aerospace, among others.
In partnership with Battery, Audio Precision and GRAS, imc will continue its long-standing tradition of pursuing growth across the sectors it serves. Joining forces with Audio Precision and GRAS, imc will benefit from business synergies across the group of companies and drive its future growth through technology development, expansion of production capabilities and an increased global market reach.
Operations for imc will continue to be based in Germany and the company’s executive team will remain in place, working closely with the group CEO Mike Flaherty to manage the business. “We are excited to welcome imc to our platform of test and measurement companies. Its highly-engineered data acquisition systems are extremely complementary to our existing portfolio of sensors and analyzers from GRAS and Audio Precision, and will broaden the market exposure of our group, enabling us to serve our customers even more effectively in the future,” said Flaherty. “We also look forward to working together to pursue additional complementary acquisitions for the group.”
“After thirty-three years of founder ownership and steady growth, this partnership brings imc many new benefits as we continue to accelerate growth globally,” said imc CEO Kai Gilbert. “We anticipate many synergies and look forward to working with Audio Precision, GRAS and Battery as we continue to develop imc’s business and deliver market-leading products to our customers.”
Battery is continuing to expand its investment activity in the industrial-technology markets and has completed more than 55 industrial-related transactions across the U.S. and Europe since 2003. For a full list of Battery portfolio companies, please click here .
About Battery
Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, online marketplaces, healthcare IT and industrial technology. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from six strategic locations: Boston; San Francisco and Menlo Park, Calif.; Tel Aviv; London; and New York. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here .
About imc Test & Measurement
Founded in 1988, imc creates tools which empower engineers to efficiently deploy data acquisition systems and test strategies, thus, meeting the test and measurement challenges of development departments world-wide. Specializing in an integrated approach to physical test and measurement, imc solutions are well suited for mixed signal testing of complex mechanical and electromechanical systems. In these situations, test engineers demand flexibility and scalable capabilities - especially when a company understands that productive testing is all about the efficient use of testing resources. Follow us on LinkedIn or visit our website: https://www.imc-tm.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005927/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 13:30:00 CEST | Press release
New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 08:30:00 CEST | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 08:00:00 CEST | Press release
New global long‑term partnership embeds Experian’s Ascend capabilities directly into ServiceNow workflows, transforming client operations Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership e
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
Boomi Teams up With Gong to Bring Revenue AI to Boomi Agentstudio14.5.2026 18:00:00 CEST | Press release
Gong's revenue AI is now natively available in the Boomi Enterprise Platform Boomi, the data activation company for AI, today announced a collaboration withGong, the leader in Revenue AI, to bring revenue signals captured in Gong natively into the Boomi Enterprise Platform. This collaboration enables enterprises to establish an active data foundation designed to transform customer conversations into coordinated, automated actions across systems and functions enterprise-wide with Boomi Agentstudio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514443012/en/ Boomi Teams Up with Gong to Bring Revenue AI to Boomi Agentstudio Gong goes beyond capturing deal activity to surface real-time insights into risk, buyer intent, competitive dynamics, and key engagement signals. That intelligence moves from conversation to coordinated action, flowing across CRM, ERP, product, and operational systems with the governance and security tha
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom